Stryker (NYSE:SYK – Get Free Report) and Curaleaf (OTCMKTS:CURLF – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.
Insider and Institutional Ownership
77.1% of Stryker shares are held by institutional investors. Comparatively, 0.0% of Curaleaf shares are held by institutional investors. 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Stryker and Curaleaf”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Stryker | $25.12 billion | 4.22 | $3.25 billion | $9.65 | 28.60 |
| Curaleaf | $1.27 billion | 1.83 | -$231.07 million | ($0.13) | -76.54 |
Stryker has higher revenue and earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current recommendations for Stryker and Curaleaf, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Stryker | 0 | 5 | 19 | 0 | 2.79 |
| Curaleaf | 0 | 0 | 2 | 3 | 3.60 |
Stryker currently has a consensus price target of $372.64, suggesting a potential upside of 35.00%. Given Stryker’s higher possible upside, research analysts clearly believe Stryker is more favorable than Curaleaf.
Profitability
This table compares Stryker and Curaleaf’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Stryker | 14.43% | 23.63% | 11.39% |
| Curaleaf | -2.62% | -0.88% | -0.26% |
Risk and Volatility
Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Curaleaf has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
Summary
Stryker beats Curaleaf on 12 of the 15 factors compared between the two stocks.
About Stryker
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
About Curaleaf
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
